ArticleTherapeutic advances in drug safety2026
Drug- and patient-specific neurological risk profiles of α1-adrenergic blockers: evidence from FAERS and external validation in JADER.
Article in Therapeutic advances in drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: α1-Adrenergic blockers are widely used in older patients, yet nervous system adverse events associated with these agents are often considered nonspecific and remain insufficiently characterized at the population level. Objectives: To evaluate nervous system adverse events associated with α1-adrenergic blockers using real-world pharmacovigilance data, assess drug-specific and patient-specific risks, and translate findings into clinically interpretable risk profiles. Design: A retrospective, observational pharmacovigilance study. Methods: We conducted an integrated pharmacovigilance analysis using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) as the discovery dataset and the Japanese Adverse Drug Event Report (JADER) database for external validation. Hierarchical signal detection within the Medical Dictionary for Regulatory Activities (MedDRA) nervous system organ class was used to construct a data-driven composite endpoint. Multivariable logistic regression with least absolute shrinkage and selection operator (LASSO)-guided feature selection estimated adjusted associations for five α1-adrenergic blockers while accounting for age, sex, and major comorbidities. Model performance and calibration were evaluated in JADER. Individualized risk portraits were generated across clinically relevant patient profiles. Results: Several α1-adrenergic blockers demonstrated significant and heterogeneous associations with nervous system adverse events in FAERS after adjustment. External validation in JADER showed consistent effect directions for drugs with sufficient exposure and acceptable calibration. Risk portrait analyses revealed marked risk stratification by age and comorbidity burden, with the highest predicted reporting probability observed among elderly patients with multiple comorbidities. Conclusion: This integrated pharmacovigilance framework provides a structured and clinically interpretable assessment of nervous system safety among α1-adrenergic blockers, highlighting the importance of agent-specific and patient-specific risk evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.